Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to ...
Managed Healthcare Executive6d
Long-Term Dupixent Treatment Shows Promising Results for Severe Atopic Dermatitis
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Eli Lilly's Ebglyss Emerges as New Option for Patients Struggling with Dupixent Treatment
Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...
Lilly's Ebglyss shown to be effective in former Dupixent users
Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...
BioSpace13d
Regeneron and Sanofi’s Dupixent Tipped to Dominate COPD Biologics Market
Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...
pharmaphorum3d
Dupixent claims new territory in eosinophilic oesophagitis
Dupixent (dupilumab) made more than €5 billion last year from its current uses in atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps, and EoE is one of a clutch ...
MedCity News29d
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...
Nasdaq1mon
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...
Pharmabiz2d
Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI
Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...
Business Insider4d
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved ...